Author: admin

Continue Reading

  • Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation

    Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation

    Patient disposition and characteristics

    Between November 23, 2021 and June 29, 2023, a total of 26 patients with pretreated mCRC harboring KRAS G12C mutation were enrolled and received single-agent garsorasib treatment. The median duration of…

    Continue Reading